Clinical Trial

Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Healthy Controls versus participants with MetSyn.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-16; most recent amendment 2026-07-23.
Trial Details
NCT Number NCT07218653
Lead Sponsor University of Wisconsin, Madison
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Metabolic Syndrome
Enrollment 72 participants
Start Date 2026-08
Primary Completion 2031-07 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-27